Versanis Presents Data Demonstrating Bimagrumab Treatment Leads to Substantial Fat Mass Loss Coupled with Lean Mass Gain in Diabetic and Non-Diabetic Patients - PR Newswire

/PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, will share analysis of Phase 2...

Dr. Lloyd Klickstein, Chief Scientific Officer of Versanis, will present the data during ENDO's Rapid Fire Poster session on Monday, June 13, from 12:30 until 1:30 p.m. EDT in Poster Pod 3, ENDOExpo … [+3396 chars]

full article...